Cambrex, a contract development and manufacturing organization (CDMO), announced that it has completed its acquisition of Snapdragon Chemistry, a US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
Snapdragon Chemistry specializes in active pharmaceutical ingredient (API) batch and continuous flow process development, utilizing automation and proprietary equipment to solve complex process and analytical development challenges. With R&D and manufacturing headquartered in Waltham, Massachusetts, Snapdragon's 70+ employees come with strong ties to the local scientific community, with 31 PhD scientists on staff.
Cambrex continues to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing, with Snapdragon bolstering its depth of expertise in continuous flow manufacturing and complementing recent investments in continuous flow process development capabilities at its High Point, North Carolina facility.